2026-04-17T12:51:05Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/115562025-10-24T08:56:23Zcom_2072_378070com_2072_378040com_2072_378071col_2072_378092col_2072_378097

00925njm 22002777a 4500 dc González-Callejo, Patricia author García-Astrain, Clara author Herrero Ruiz, Ada author Henriksen-Lacey, Malou author Seras-Franzoso, Joaquin author Abasolo, Ibane author 2024-06-06T05:47:14Z 2024-06-06T05:47:14Z 2024-05-29 3D bioprinting; Cancer stem cells; Triple-negative breast cancer Bioimpresión 3D; Células madre cancerosas; Cáncer de mama triple negativo Bioimpressió 3D; Cèl·lules mare cancerígenes; Càncer de mama triple negatiu Breast cancer stem cells (CSCs) play a pivotal role in therapy resistance and tumor relapse, emphasizing the need for reliable in vitro models that recapitulate the complexity of the CSC tumor microenvironment to accelerate drug discovery. We present a bioprinted breast CSC tumor-stroma model incorporating triple-negative breast CSCs (TNB-CSCs) and stromal cells (human breast fibroblasts), within a breast-derived decellularized extracellular matrix bioink. Comparison of molecular signatures in this model with different clinical subtypes of bioprinted tumor-stroma models unveils a unique molecular profile for artificial CSC tumor models. We additionally demonstrate that the model can recapitulate the invasive potential of TNB-CSC. Surface-enhanced Raman scattering imaging allowed us to monitor the invasive potential of tumor cells in deep z-axis planes, thereby overcoming the depth-imaging limitations of confocal fluorescence microscopy. As a proof-of-concept application, we conducted high-throughput drug testing analysis to assess the efficacy of CSC-targeted therapy in combination with conventional chemotherapeutic compounds. The results highlight the usefulness of tumor-stroma models as a promising drug-screening platform, providing insights into therapeutic efficacy against CSC populations resistant to conventional therapies. Funding Sources Financial support was provided by the European Research Council (ERC-AdG-2017 #787510 4DBIOSERS and ERC-2023-POC #101138255 3DTUMOUR). C.G.A. thanks the Spanish State Research Agency for a Juan de la Cierva Incorporación Fellowship (FJCI-2016-28887). I.A. is grateful for the SGR grant from the Catalan Government (2021 SGR 1173). Figures were created using BioRender. http://hdl.handle.net/11351/11556 Medicaments antineoplàstics - Ús terapèutic Impressió 3D Mama - Càncer - Tractament Cèl·lules mare TECHNOLOGY, INDUSTRY, AND AGRICULTURE::Technology, Industry, and Agriculture::Technology::Printing, Three-Dimensional DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms ANATOMY::Cells::Stem Cells::Neoplastic Stem Cells CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment TECNOLOGÍA, INDUSTRIA Y AGRICULTURA::tecnología, industria y agricultura::tecnología::impresión tridimensional ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos ANATOMÍA::células::células madre::células madre neoplásicas FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos 3D Bioprinted Tumor-Stroma Models of Triple-Negative Breast Cancer Stem Cells for Preclinical Targeted Therapy Evaluation